<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Statins; Atorvastatin; Fluvastatin; Rosuvastatin; Simvastatin; Pravastatin; Cardiovascular disease: prevention: dyslipidaemia; Cardiovascular disease: risk assessment; Hypercholesterolaemia" /><meta name="IX" content="Statins; Atorvastatin; Fluvastatin; Rosuvastatin; Simvastatin; Pravastatin; Cardiovascular disease: prevention: dyslipidaemia; Cardiovascular disease: risk assessment; Hypercholesterolaemia" /><title>Statins: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="33422.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="33422.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=33422.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="2836.htm">2.12 Lipid-regulating drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="2836.htm" title="Previous: 2.12 Lipid-regulating drugs">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="60589.htm" title="Next: ATORVASTATIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_33422">Statins</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i600.htm" title="Go to appendix 1">Statins</a>).</div><div><p>The statins (<b>atorvastatin</b>, <b>fluvastatin</b>, <b>pravastatin</b>, <b>rosuvastatin</b>, and <b>simvastatin</b>) competitively inhibit 3-hydroxy-3-methylglutaryl
coenzyme A (HMG CoA) reductase, an enzyme involved in cholesterol
synthesis, especially in the liver. Statins are more effective than
other lipid-regulating drugs at lowering LDL-cholesterol concentration
but they are less effective than the fibrates in reducing triglyceride
concentration. However, statins reduce cardiovascular disease events
and total mortality irrespective of the initial cholesterol concentration.</p><p>Statins should be considered for all patients, including the
elderly, with symptomatic cardiovascular disease such as those with
coronary heart disease (including history of angina or acute myocardial
infarction), occlusive arterial disease (including peripheral vascular
disease, non-haemorrhagic stroke, or transient ischaemic attacks).</p><div id="_33422.7"><p>In patients
with diabetes mellitus, the risk of developing cardiovascular disease
depends on the duration and complications of diabetes, age, and concomitant
risk factors. Statin therapy should be considered for <i>all</i> patients over 40 years with diabetes mellitus (type 1 and 2). In
younger patients with diabetes, treatment with a statin should be
considered if there is target-organ damage, poor glycaemic control
(HbA<sub>1c</sub> greater than 9%), low HDL-cholesterol and raised
triglyceride concentration, hypertension, or a family history of premature
cardiovascular disease.</p></div><p>Statins are also used for the prevention of cardiovascular
disease events in asymptomatic individuals who are at increased risk
(see <a title="section: Lipid-regulating drugs" href="2836.htm#_2836">Lipid-regulating drugs</a>).
Statin treatment should also be considered if the total cholesterol
concentration to HDL-cholesterol ratio exceeds 6.</p><div class="cAZ"><h2>Cautions</h2> <p class="cAX"><span id="_33422.5">Hypothyroidism should be managed
adequately before starting treatment with a statin (see <a title="target-block: lipid-regulating drugs in hypothyroidism" href="2836.htm#_2836.2">Lipid-regulating drugs</a>).
Statins should be used with caution in those with a history
of liver disease or with a high <span>alcohol</span> intake—see also Hepatic impairment,
below. There is little information available on a rational approach
to liver-function monitoring; however, a NICE guideline<sup class="footnote"><a title="Go to footnote" href="33422.htm#footnote201051">(1)</a></sup> suggests that liver enzymes should be
measured before treatment, and repeated within 3 months and at 12
months of starting treatment, unless indicated at other times by signs
or symptoms suggestive of hepatotoxicity. Those with serum transaminases
that are raised, but less than 3 times the upper limit of the reference
range, should <b>not</b> be routinely excluded from statin
therapy. Those with serum transaminases of more than 3 times the upper
limit of the reference range should discontinue statin therapy. Statins
should be used with caution in those with risk factors
for myopathy or rhabdomyolysis (see Muscle Effects
below); patients should be advised to report unexplained muscle pain. </span><span id="_33422.6">Statins should
be avoided in acute porphyria (<a title="monograph-family: Drugs unsafe for use in acute porphyrias" href="34979.htm#_34979">section 9.8.2</a>) but
rosuvastatin is thought to be safe.</span> <b>Interactions:</b> Appendix 1 (statins).</p></div><div id="_203977"><div class="cAZ"><h2>Hepatic impairment</h2> <p class="cAX">Statins should be used with
caution in those with a history of liver disease and avoided in active
liver disease or when there are unexplained persistent elevations
in serum transaminases.</p></div></div><div id="_203980"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">Statins should be avoided in pregnancy
as congenital anomalies have been reported and the decreased synthesis
of cholesterol possibly affects fetal development. Adequate contraception
is required during treatment and for 1 month afterwards.</p></div></div><div id="_203982"><div class="cAZ"><h2>Breast-feeding</h2> <p class="cAX">The manufacturers of atorvastatin,
fluvastatin, rosuvastatin, and simvastatin advise avoiding use in
mothers who are breast-feeding as there is no information available.
The manufacturers of pravastatin advise against use in breast-feeding
mothers as a small amount of drug is present in breast milk.</p></div></div><div id="_208048"><div class="cAZ" id="_33422.3"><h2>Side-effects</h2> <p class="cAX">The statins have been associated
with myalgia, myopathy, myositis, and rhabdomyolysis (see Muscle Effects
below). Statins can alter liver function tests, and rarely cause hepatitis
and jaundice; pancreatitis and hepatic failure have been reported
very rarely. Other side-effects include gastro-intestinal disturbances,
sleep disturbance, headache, dizziness, depression, paraesthesia,
asthenia, peripheral neuropathy, amnesia, fatigue, sexual dysfunction,
thrombocytopenia, arthralgia, visual disturbance, alopecia, and hypersensitivity
reactions (including rash, pruritus, urticaria, and very rarely lupus
erythematosus-like reactions). In very rare cases, statins can cause
interstitial lung disease; if patients develop symptoms such as dyspnoea,
cough, and weight loss, they should seek medical attention.</p><div class="cAR"><h3>Muscle effects</h3> <p class="cAX">The risk of myopathy, myositis,
and rhabdomyolysis associated with statin use is rare. Although myalgia
has been reported commonly in patients receiving statins, muscle toxicity
truly attributable to statin use is rare. Muscle toxicity can occur
with all statins, however the likelihood increases with higher doses
and in certain patients (see below). Statins should be used with caution
in patients at increased risk of muscle toxicity, including those
with a personal or family history of muscular disorders, previous
history of muscular toxicity, a high alcohol intake, renal impairment,
hypothyroidism, and in the elderly. There is an increased incidence
of myopathy if a statin is given at a high dose, or if it is given
with a fibrate (the combination of a statin and gemfibrozil should
preferably be avoided), with lipid-lowering doses of nicotinic acid,
with fusidic acid (risk of rhabdomyolysis—the combination of a statin
and fusidic acid should be avoided; temporarily discontinue statin
and restart 7 days after last fusidic acid dose), or with drugs that
increase the plasma-statin concentration, such as macrolide antibiotics,
imidazole and triazole antifungals, and ciclosporin—see <b>interactions</b>: Appendix 1 (statins); close monitoring of liver function and, if
muscular symptoms occur, of creatine kinase is necessary. In patients
at increased risk of muscle effects, a statin should not usually be
started if the baseline creatine kinase concentration is more than
5 times the upper limit of normal (some patients may present with
an extremely elevated baseline creatine kinase concentration, due
to e.g. a physical occupation, or rigorous exercise—specialist advice
should be sought regarding consideration of statin therapy in these
patients).</p><p>If muscular symptoms or raised creatine kinase occur during
treatment, other possible causes (e.g. rigorous physical activity,
hypothyroidism, infection, recent trauma, and drug or alcohol addiction)
should be excluded before statin therapy is implicated. When a statin
is suspected to be the cause of myopathy, and creatine kinase concentration
is markedly elevated (more than 5 times upper limit of normal), or
if muscular symptoms are severe, treatment should be discontinued.
If symptoms resolve and creatine kinase concentrations return to normal,
the statin should be reintroduced at a lower dose and the patient
monitored closely; an alternative statin should be prescribed if unacceptable
side-effects are experienced with a particular statin. Statins should
not be discontinued in the event of small, asymptomatic elevations
of creatine kinase. Routine monitoring of creatine kinase is unnecessary
in asymptomatic patients.</p></div></div></div><div class="cAZ" id="_33422.4"><h2>Counselling</h2> <p class="cAX">Advise patient to report
promptly unexplained muscle pain, tenderness, or weakness.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_60589"><a href="60589.htm" title="ATORVASTATIN">ATORVASTATIN</a></li><li id="_23230"><a href="23230.htm" title="FLUVASTATIN">FLUVASTATIN</a></li><li id="_2868"><a href="2868.htm" title="PRAVASTATIN SODIUM">PRAVASTATIN SODIUM</a></li><li id="_128042"><a href="128042.htm" title="ROSUVASTATIN">ROSUVASTATIN</a></li><li id="_2870"><a href="2870.htm" title="SIMVASTATIN">SIMVASTATIN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="2836.htm">Previous: 2.12 Lipid-regulating drugs</a> | <a class="top" href="33422.htm#">Top</a> | <a accesskey="]" href="60589.htm">Next: ATORVASTATIN</a> ►</div><div class="cF"><div class="footnote" id="footnote201051"><sup>(1)</sup>NICE clinical guideline 67 (May 2008). Lipid Modification—Cardiovascular
risk assessment and the modification of blood lipids for the primary
and secondary prevention of cardiovascular disease</div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>